BMS-794833 reduces anlotinib resistance in osteosarcoma by targeting the VEGFR/Ras/CDK2 pathway

Qingtao Meng(The Third People's Hospital of Dalian City), Wenzhi Zhao(Second Affiliated Hospital of Dalian Medical University)
Journal of bone oncology
March 16, 2024
Cited by 6


Related Papers